
Current Price | $13.85 | Mkt Cap | $887.6M |
---|---|---|---|
Open | $13.77 | P/E Ratio | 31.35 |
Prev. Close | $13.85 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $13.66 - $13.96 | Volume | 496,643 |
52-Wk Range | $10.64 - $14.08 | Avg. Daily Vol. | 689,451 |
A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.
Current Price | $13.85 | Mkt Cap | $887.6M |
---|---|---|---|
Open | $13.77 | P/E Ratio | 31.35 |
Prev. Close | $13.85 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $13.66 - $13.96 | Volume | 496,643 |
52-Wk Range | $10.64 - $14.08 | Avg. Daily Vol. | 689,451 |
The best Bull and Bear pitches based on recency and number of recommendations.
Therevance appears to be a good company, but hit a rough spot. Should rebound from here.
The recent bull charge has carried several baby biotechs and small pharmas out of their trading range without positive catalysts, which primes them for disproportionate drops as soon as the momentum inevitably shifts. Theravance has been bouncing… More
Read the most recent pitches from players about INVA.
Recs
Grow and more Grow!
Recs
Pharma isn't my favorite but I do like the valuation and dividend on this. Not without it's risks.
Recs
undervalued
Find the members with the highest scoring picks in INVA.
Evad005 (< 20) Score: +454.61
The Score Leader is the player with the highest score across all their picks in INVA.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
Evad005 | < 20 | 3/25/2009 |
![]() |
3M | $12.24 | +13.11% | +467.72% | +454.61 | 0 Comment | |
jmacn22 | 29.45 | 2/5/2009 |
![]() |
3Y | $11.97 | +15.75% | +447.86% | +432.11 | 1 Comment | |
anticitradeshort | 28.29 | 4/20/2009 |
![]() |
NS | $10.36 | +33.68% | +439.11% | +405.43 | 0 Comment | |
qubit15 | 26.77 | 1/21/2009 |
![]() |
NS | $8.07 | +71.73% | +470.25% | +398.52 | 0 Comment | |
schwah4 | 26.98 | 12/29/2008 |
![]() |
NS | $8.23 | +68.35% | +441.91% | +373.56 | 0 Comment | |
haimp | < 20 | 10/7/2010 |
![]() |
5Y | $15.87 | -12.70% | +293.96% | +306.66 | 0 Comment | |
anticitrademix2 | < 20 | 11/2/2009 |
![]() |
5Y | $10.31 | +34.34% | +338.30% | +303.95 | 0 Comment | |
anticitrademix | < 20 | 11/2/2009 |
![]() |
5Y | $10.31 | +34.34% | +338.30% | +303.95 | 0 Comment | |
alexdowns77 | 75.43 | 10/1/2010 |
![]() |
5Y | $14.54 | -4.75% | +299.16% | +303.91 | 0 Comment | |
withoutlimits | 84.94 | 10/1/2010 |
![]() |
5Y | $14.84 | -6.69% | +296.90% | +303.59 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.